頁籤選單縮合
題 名 | Nintedanib治療原發性肺纖維化=Nintedanib Treating Idiopathic Pulmonary Fibrosis |
---|---|
作 者 | 劉玉琴; 吳求珍; | 書刊名 | 藥學雜誌 |
卷 期 | 31:2=123 2015.06[民104.06] |
頁 次 | 頁38-42 |
分類號 | 418.31 |
關鍵詞 | 原發性肺纖維化; Nintedanib; Idiopathic pulmonary fibrosis; |
語 文 | 中文(Chinese) |
中文摘要 | 原發性肺纖維化 (Idiopathic pulmonary fibrosis, IPF) 是間質性肺炎的一種,發生原 因不明,發病過程屬慢性、漸進性。輕度時常造成患者乾咳、呼吸困難、中重度時會 讓咳嗽加劇、體力衰弱、肺功能逐漸喪失。發生率和年齡成正相關,主要發生在50歲 以上的老年人。早期認為是慢性發炎導致肺間質纖維化,在治療藥物選擇降低發炎反 應及免疫調節劑,後來研究發現肺泡上皮細胞和纖維母細胞間質有功能異常現象,而 且和活化細胞訊息傳遞有關,因此造成纖維細胞異常增生和組織重塑 (remodeling)。 2014年10月15日 FDA 核准 nintedanib 上市,屬於新型治療原發性肺纖維化藥物,可 以阻斷細胞內的訊號傳遞、抑制纖維母細胞的增生、轉移和改變,減少用力肺活量 (forced vital capacity, FVC) 的下降率,延緩疾病的進程,降低肺功能的惡化速率。 |
英文摘要 | Idiopathic pulmonary fibrosis is a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown causes, occurring in adults. In the past, treatment was aimed for anti-inflammation and immune modulation. Current evidence indicates that it arises from an aberrant proliferation of fibroblasts and tissue remodeling due to the abnormal function and signaling of alveolar epithelial cells and interstitial fibroblasts. Since October 15, 2014 FDA approved nintedanib, it is a new type of drug for treatment of idiopathic pulmonary fibrosis. It can blocks the intracellular signaling which is crucial for the proliferation, migration, and transformation of fibroblasts. Nintedanib significantly reducing the annual rate of FVC decline, delaying progression of the disease and reducing the rate of deterioration of lung function. |
本系統中英文摘要資訊取自各篇刊載內容。